LTP2 Results Analysis-LaBaer (2024)

Abbreviated Name
LTP2 Results Analysis-LaBaer (2024)
Lead Investigator
LaBaer, JoshuaArizona State University
Coordinating Investigator
Zheng, Yingye Fred Hutchinson Cancer Center
Involved Investigators

Abstract

We will assess the performance of the candidate antibody biomarkers using ELISA and the candidate serum protein markers using the MSD platform in the 346 serum samples from the Lung Team Project 2 (LTP2).

Aims

We will assess the performance of the candidate antibody biomarkers using ELISA and the candidate serum protein markers using the MSD platform in the 346 serum samples from the Lung Team Project 2 (LTP2).

Analytic Method

Analyzed by DMCC

Outcome

We will assess the performance of the candidate antibody biomarkers using ELISA and the candidate serum protein markers using the MSD platform in the 346 serum samples from the Lung Team Project 2 (LTP2).

Publications

  • No publications available at this time for this protocol.

Biomarkers

  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
Start Date
Nov 1 2024
Estimated Finish Date
May 1 2025
Protocol ID
559
Protocol Type
Validation
Fields of Research
  • Genomics
  • Proteomics
Collaborative Group
Lung and Upper Aerodigestive Cancers Research Group
Cancer Types
  • Malignant neoplasm of bronchus and lung
Phased Status
2

Associated Forms